Pancreatic Cancer Research

ResearcherUniversity of Tokyo HospitalActive in the last 2 years

Kazunaga Ishigaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6773-9465; OpenAlex author ID A5041336149, A5125721119. Sources: OpenAlex.

Their work

Papers
25 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 5 papers · 2026: 4 papers

Papers 25

  1. Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovori… First author DOI 10.1007/s00520-026-10845-1↗
  2. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  3. Prediction model for ctDNA detectability in liquid comprehensive genomic profiling of advanced pancreatic cancer based on Japanese real-world data. Co-author DOI 10.1016/j.esmoop.2026.106069↗
  4. Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Co-author DOI 10.1016/j.hpb.2025.12.021↗
  5. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Co-author DOI 10.1007/s00535-024-02173-0↗
  6. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. First author DOI 10.1007/s00535-025-02253-9↗
  7. Relationship of Intrapancreatic Fat Deposition With Pancreatic Cancer Differs According to Carcinoma Types. Co-author DOI 10.1053/j.gastro.2025.04.032↗
  8. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… Co-author DOI 10.1136/gutjnl-2024-333259↗
  9. Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstru… Co-author DOI 10.5946/ce.2024.031↗
  10. CA19-9-Positive Extracellular Vesicle Is a Risk Factor for Cancer-Associated Thrombosis in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2024.02.005↗
  11. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  12. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. Co-author DOI 10.1016/j.isci.2023.106021↗
  13. Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins. Co-author DOI 10.1002/ctm2.1089↗
  14. Smaller extracellular vesicles are released from pancreatic cancer cells by the alteration of the lipid composition under low glucose conditions. Co-author DOI 10.1016/j.bbrc.2022.11.040↗
  15. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  16. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  17. Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A… Co-author DOI 10.1016/j.clnu.2021.06.011↗
  18. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  19. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  20. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  21. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  22. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  23. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  24. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  25. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuhiro Fujishiro · 13 shared papers, 2022–2026 · strength 2.87
  2. Naminatsu Takahara · 18 shared papers, 2015–2026 · strength 2.43
  3. Yousuke Nakai · 19 shared papers, 2015–2026 · strength 2.39
  4. Tsuyoshi Hamada · 14 shared papers, 2015–2025 · strength 1.76
  5. Tatsunori Suzuki · 7 shared papers, 2023–2026 · strength 1.38
  6. Hiroki Oyama · 7 shared papers, 2020–2025 · strength 1.17
  7. Kei Saito · 12 shared papers, 2015–2023 · strength 1.00
  8. Kazuhiko Koike · 12 shared papers, 2015–2023 · strength 0.98
  9. Takahiro Kishikawa · 6 shared papers, 2015–2024 · strength 0.87
  10. Chikako Shibata · 4 shared papers, 2022–2024 · strength 0.76
  11. Takahiro Seimiya · 4 shared papers, 2022–2024 · strength 0.76
  12. Motoyuki Otsuka · 4 shared papers, 2022–2024 · strength 0.76
  13. Suguru Mizuno · 10 shared papers, 2015–2021 · strength 0.71
  14. Hirofumi Kogure · 10 shared papers, 2015–2021 · strength 0.71
  15. Tomotaka Saito · 8 shared papers, 2015–2023 · strength 0.70
  16. Hidenori Kage · 3 shared papers, 2025–2026 · strength 0.68
  17. Hideaki Ijichi · 8 shared papers, 2015–2023 · strength 0.66
  18. Yurie Tokito · 3 shared papers, 2025–2026 · strength 0.66
  19. Go Endo · 3 shared papers, 2025–2026 · strength 0.66
  20. Hiroyuki Isayama · 9 shared papers, 2015–2021 · strength 0.60
  21. Kiyoshi Hasegawa · 3 shared papers, 2018–2026 · strength 0.52
  22. Narikazu Boku · 2 shared papers, 2026 · strength 0.51
  23. Koji Miyabayashi · 4 shared papers, 2015–2025 · strength 0.45
  24. Minoru Tada · 7 shared papers, 2015–2019 · strength 0.40
  25. Maxim S. Petrov · 2 shared papers, 2025 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.